Fulltext Search
363 Sales as a Health Care M&A Tool, Part 2 - Pros and Cons for Buyers and Sellers

 

Over the summer, we wrote about why health care companies may want to consider buying assets out of bankruptcy, taking advantage of the Bankruptcy Code Section 363 sale process (a “363 Sale”). We are back with our second post, to provide more detail to the process and discuss some pros and cons of 363 Sales.

USA, Insolvency & Restructuring, Litigation, Mintz, Due diligence, Non-disclosure agreement, Title 11 of the US Code
363 Sales as a Health Care M&A Tool, Part 1 - Overview

This two-part blog series discusses why buyers looking to make strategic purchases in the health care industry might want to take advantage of the Bankruptcy Code Section 363 sale process (363 Sale) and the pros and cons of buying assets out of bankruptcy through a 363 Sale.

USA, Healthcare & Life Sciences, Insolvency & Restructuring, Mintz, Due diligence, Coronavirus
Proposed insolvency (and other) relief for businesses impacted by COVID-19

Finance Minister Grant Robertson yesterday afternoon announced a number of proposed temporary changes to the Companies Act, with the stated purpose to help businesses facing insolvency due to COVID-19 remain viable.

The temporary changes include:

New Zealand, Company & Commercial, Insolvency & Restructuring, Buddle Findlay, Coronavirus